Media headlines about Masimo (NASDAQ:MASI) have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Masimo earned a news impact score of 0.19 on Accern’s scale. Accern also gave headlines about the medical equipment provider an impact score of 46.0453743307326 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Moving & Shaking: ETTA Celebrates; Federation Honors Bruce Powell (jewishjournal.com)
- Parrish Medical Center Awarded Patient Safety Movement’s First 5-Star Hospital Ranking (businesswireindia.com)
- Masimo wins home-use indication for Rad-97 pulse CO-Oximeter (massdevice.com)
- Masimo Corp. (MASI) Announces FDA Clearance for Home Use of Rad-97 (streetinsider.com)
- Save Lives, Fish with President Carter and Patient Safety Movement Foundation (businesswireindia.com)
Masimo (MASI) traded down $0.32 during mid-day trading on Thursday, hitting $85.78. The stock had a trading volume of 413,757 shares, compared to its average volume of 378,640. The stock has a market capitalization of $4,430.00, a price-to-earnings ratio of 13.59, a PEG ratio of 3.41 and a beta of 0.72. Masimo has a 1-year low of $69.57 and a 1-year high of $104.71.
Several research firms have commented on MASI. Zacks Investment Research upgraded Masimo from a “hold” rating to a “buy” rating and set a $98.00 price objective for the company in a research note on Thursday, November 2nd. Stifel Nicolaus reiterated a “buy” rating and set a $108.00 price objective on shares of Masimo in a research note on Friday, November 3rd. Finally, BidaskClub lowered Masimo from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $97.17.
In related news, Director Steven Barker sold 10,000 shares of the stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $90.00, for a total value of $900,000.00. Following the completion of the transaction, the director now directly owns 73,249 shares in the company, valued at $6,592,410. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Yongsam Lee sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $89.89, for a total value of $449,450.00. Following the completion of the transaction, the executive vice president now owns 74,000 shares of the company’s stock, valued at $6,651,860. The disclosure for this sale can be found here. Insiders sold 63,074 shares of company stock valued at $5,618,945 over the last 90 days. Company insiders own 13.10% of the company’s stock.
Masimo Company Profile
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.